Emily S. Riser, MD
Specialist
- Medicare participating
At a glance
- Medical school
- University of Alabama School of Medicine (1984)
- Years since graduation
- 42
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 215
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1984Medical school: University of Alabama School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Specialist primary
AL license AL12139
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Baptist Medical Center South Montgomery, AL
Medical groups
- Alabama Neurology Associates (14 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 215
- Services billed
- 34,968
- Patients’ average age
- 64
| Service | Times | Patients |
|---|---|---|
| Injection, methylprednisolone sodium succinate, up to 125 mg | 279 | 18 |
| Established patient office or other outpatient visit, 30-39 minutes | 252 | 149 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 134 | 20 |
| Injection of additional new drug or substance into vein | 45 | 13 |
| Administration of chemotherapy into vein, 1 hour or less | 33 | 15 |
| Administration of chemotherapy into vein, each additional hour | 26 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Gabapentin Other prescribers in Birmingham, AL | 638 |
| Dextroamphetamine-Amphetamine (dextroamphetamine/amphetamine) Other prescribers in Birmingham, AL | 467 |
| Baclofen Other prescribers in Birmingham, AL | 435 |
| Clonazepam Other prescribers in Birmingham, AL | 351 |
| Tizanidine Hcl Other prescribers in Birmingham, AL | 298 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Birmingham, AL | 296 |
| Zolpidem Tartrate Other prescribers in Birmingham, AL | 201 |
| Tramadol Hcl Other prescribers in Birmingham, AL | 185 |
| Alprazolam Other prescribers in Birmingham, AL | 182 |
| Dalfampridine Er (dalfampridine) | 146 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 24 companies reported 193 payments worth $22,117 in total to this clinician.
| Tg Therapeutics, Inc. | $18,570 |
|---|---|
| Neurocrine Biosciences, Inc. | $465 |
| Biogen, Inc. | $343 |
| Alexion Pharmaceuticals, Inc. | $285 |
| Novartis Pharmaceuticals Corporation | $285 |
| Pfizer Inc. | $252 |
| Genentech USA, Inc. | $232 |
| Janssen Biotech, Inc. | $225 |
| Compensation for services other than consulting (speaking, faculty) | $16,478 |
|---|---|
| Food and Beverage | $4,195 |
| Travel and Lodging | $1,349 |
| Education | $94.99 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Tg Therapeutics, Inc. Jun 12, 2025 | Compensation for services other than consulting (speaking, faculty) BRIUMVI · Immunology | $3,713 |
| Tg Therapeutics, Inc. Jun 19, 2025 | Compensation for services other than consulting (speaking, faculty) BRIUMVI · Immunology | $3,713 |
| Tg Therapeutics, Inc. Dec 11, 2025 | Compensation for services other than consulting (speaking, faculty) BRIUMVI · Immunology | $3,713 |
| Tg Therapeutics, Inc. Jul 24, 2025 | Compensation for services other than consulting (speaking, faculty) BRIUMVI · Immunology | $3,713 |
| Tg Therapeutics, Inc. Jun 19, 2025 | Travel and Lodging BRIUMVI · Immunology · travel to Anniston, AL · in-kind | $745 |
| Tg Therapeutics, Inc. Jun 12, 2025 | Travel and Lodging BRIUMVI · Immunology · travel to Tuscaloosa, AL · in-kind | $604 |
| Tg Therapeutics, Inc. Jun 11, 2025 | Compensation for services other than consulting (speaking, faculty) BRIUMVI · Immunology | $465 |
| Tg Therapeutics, Inc. Nov 12, 2025 | Compensation for services other than consulting (speaking, faculty) BRIUMVI · Immunology | $465 |
| Tg Therapeutics, Inc. Mar 25, 2025 | Compensation for services other than consulting (speaking, faculty) BRIUMVI · Immunology | $465 |
| Tg Therapeutics, Inc. Oct 23, 2025 | Compensation for services other than consulting (speaking, faculty) BRIUMVI · Immunology | $233 |
All 11 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Tg Therapeutics, Inc. Dec 11, 2025 | Compensation for services other than consulting (speaking, faculty) BRIUMVI · Immunology | $3,713 |
| Janssen Biotech, Inc. Dec 10, 2025 | Education in-kind | $94.99 |
| Tg Therapeutics, Inc. Nov 12, 2025 | Compensation for services other than consulting (speaking, faculty) BRIUMVI · Immunology | $465 |
| Tg Therapeutics, Inc. Oct 23, 2025 | Compensation for services other than consulting (speaking, faculty) BRIUMVI · Immunology | $233 |
| Tg Therapeutics, Inc. Jul 24, 2025 | Compensation for services other than consulting (speaking, faculty) BRIUMVI · Immunology | $3,713 |
| Tg Therapeutics, Inc. Jun 19, 2025 | Compensation for services other than consulting (speaking, faculty) BRIUMVI · Immunology | $3,713 |
| Tg Therapeutics, Inc. Jun 19, 2025 | Travel and Lodging BRIUMVI · Immunology · travel to Anniston, AL · in-kind | $745 |
| Tg Therapeutics, Inc. Jun 12, 2025 | Compensation for services other than consulting (speaking, faculty) BRIUMVI · Immunology | $3,713 |
| Tg Therapeutics, Inc. Jun 12, 2025 | Travel and Lodging BRIUMVI · Immunology · travel to Tuscaloosa, AL · in-kind | $604 |
| Tg Therapeutics, Inc. Jun 11, 2025 | Compensation for services other than consulting (speaking, faculty) BRIUMVI · Immunology | $465 |
| Tg Therapeutics, Inc. Mar 25, 2025 | Compensation for services other than consulting (speaking, faculty) BRIUMVI · Immunology | $465 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 13 industry-funded studies in 2025, from 6 companies. The companies reported $2,175,110 in research payments for these studies, mostly to the institutions running them.
- (ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study
Tg Therapeutics, Inc. - Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
Genzyme Corporation · Active, not recruiting · NCT06141486 - Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
Genzyme Corporation · Active, not recruiting · NCT06141473 - (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab
Tg Therapeutics, Inc. - Ocrelizumab RMS High Dose Study
Genentech, Inc. - Evaluation of Fenebrutinib in RMS patients
Genentech, Inc. - A phase iii study to evaluate the efficacy and safety of fenebrutinib in adults with progressive ms
Genentech, Inc. - A Pilot Open-Label, Randomized, Multi-Center, Parall el-Arm, of Acute vs Delay Ofatumumab Treatment d uring an Acute Multiple Sclerosis Relapse
Novartis Pharmaceuticals Corporation - A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After …
Novartis Pharmaceuticals Corporation - Ocrelizumab PPMS High Dose Study
Genentech, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.